BCM
ACOR

Bayesian Capital Management’s Acorda Therapeutics ACOR Stock Holding History

Bayesian Capital Management’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-121
Closed -$10K – 735
2020
Q4 		$10K Buy
+121
New +$11.1K ﹤0.01% 430
2019
Q1 		– Sell
-99
Closed -$185K – 804
2018
Q4 		$185K Buy
+99
New +$215K 0.04% 524

Other funds holding ACOR

Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
CCA
Canyon Capital Advisors Dallas, Texas $772M AUM 32.81% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Bayesian Capital Management's ACOR Position: Q1 2021 in Review

Bayesian Capital Management sold out of Acorda Therapeutics (ACOR) in Q1 2021, closing a stake of 121 shares — an estimated $10K sold.

Bayesian Capital Management first reported a position in ACOR in Q4 2018 and held it in 2 quarters. The position peaked at $185K in Q4 2018. 32 funds tracked by Wall St. Rank hold ACOR as of Q1 2021.

  • Bayesian Capital Management reported no remaining Acorda Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Bayesian Capital Management sold 121 Acorda Therapeutics shares in Q1 2021, an estimated $10K.
  • Bayesian Capital Management first reported a position in Acorda Therapeutics in Q4 2018 and held it in 2 quarters.
  • Bayesian Capital Management's Acorda Therapeutics position peaked at $185K in Q4 2018.
  • 32 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q1 2021.

Based on Bayesian Capital Management's 13F filing for Q1 2021, filed 14 May 2021.